Management of NAFLD: a stage-based approach (Q38747405)

6 September 2017

Management of NAFLD: a stage-based approach (English)

1 reference

6 September 2017

Mary E Rinella

1

1 reference

PubMed ID

26907882

6 September 2017

Arun J Sanyal

series ordinal

2

1 reference

PubMed ID

26907882

6 September 2017

language of work or name

English

0 references

publication date

24 February 2016

1 reference

Nature Reviews Gastroenterology & Hepatology

6 September 2017

1 reference

6 September 2017

13

1 reference

6 September 2017

4

1 reference

6 September 2017

196-205

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2016.3

6 September 2017

0 references

cites work

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Liver fibrosis in overweight patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Alterations in hepatic glucose and energy metabolism as a result of calorie and carbohydrate restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Refeeding with glucose rather than fructose elicits greater hepatic inflammatory gene expression in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Association of coffee drinking with total and cause-specific mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Alcohol, smoking, coffee, and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT/RT

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Night eating syndrome: implications for severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Long-term mortality after gastric bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Non-alcoholic fatty liver disease: is bariatric surgery the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Hospital complication rates with bariatric surgery in Michigan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A Systematic Review of Bariatric Surgery in Patients with Liver Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Unleashing the untold and misunderstood observations on vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Vitamin E supplementation and mortality in healthy people: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Meta-analysis: low-dose intake of vitamin E combined with other vitamins or minerals may decrease all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Health implications of high dietary omega-6 polyunsaturated Fatty acids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A lipidomic analysis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Coordinated control of bile acids and lipogenesis through FXR-dependent regulation of fatty acid synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Farnesoid X receptor represses hepatic lipase gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

HDL cholesterol efflux capacity and incident cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

A natural product that lowers cholesterol as an antagonist ligand for FXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Fibrosis--a common pathway to organ injury and failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Liver fibrosis and repair: immune regulation of wound healing in a solid organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The liver diseases of lipodystrophy: the long-term effect of leptin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2016.3

Plasma bile acids show a positive correlation with body mass index and are negatively associated with cognitive restraint of eating in obese patients

31 March 2020

1 reference

12 December 2020

Stomal complications of gastric bypass: incidence and outcome of therapy

1 reference

12 December 2020

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

1 reference

12 December 2020

Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial

1 reference

12 December 2020

Impact of cholesterol metabolism and the LXRalpha-SREBP-1c pathway on nonalcoholic fatty liver disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2016.3

1 reference

6 September 2017

1 reference

PubMed ID

26907882